4.6 Article

Vitrectomy Outcomes in Eyes with Diabetic Macular Edema and Vitreomacular Traction

期刊

OPHTHALMOLOGY
卷 117, 期 6, 页码 1087-U86

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2009.10.040

关键词

-

资金

  1. National Eye Institute
  2. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services [EY14231, EY14269, EY14229]

向作者/读者索取更多资源

Purpose: To evaluate vitrectomy for diabetic macular edema (DME) in eyes with at least moderate vision loss and vitreomacular traction. Design: Prospective cohort study. Participants: The primary cohort included 87 eyes with DME and vitreomacular traction based on investigator's evaluation, visual acuity 20/63-20/400, optical coherence tomography (OCT) central subfield >300 microns and no concomitant cataract extraction at the time of vitrectomy. Methods: Surgery was performed according to the investigator's usual routine. Follow-up visits were performed after 3 months, 6 months (primary end point), and 1 year. Main Outcome Measures: Visual acuity, OCT retinal thickening, and operative complications. Results: At baseline, median visual acuity in the 87 eyes was 20/100 and median OCT thickness was 491 microns. During vitrectomy, additional procedures included epiretinal membrane peeling in 61%, internal limiting membrane peeling in 54%, panretinal photocoagulation in 40%, and injection of corticosteroids at the close of the procedure in 64%. At 6 months, median OCT central subfield thickness decreased by 160 microns, with 43% having central subfield thickness <250 microns and 68% having at least a 50% reduction in thickening. Visual acuity improved by >= 10 letters in 38% (95% confidence interval, 28%-49%) and deteriorated by >= 10 letters in 22% (95% confidence interval, 13%-31%). Postoperative complications through 6 months included vitreous hemorrhage (5 eyes), elevated intraocular pressure requiring treatment (7 eyes), retinal detachment (3 eyes), and endophthalmitis (1 eye). Few changes in results were noted between 6 months and 1 year. Conclusions: After vitrectomy performed for DME and vitreomacular traction, retinal thickening was reduced in most eyes. Between 28% and 49% of eyes with characteristics similar to those included in this study are likely to have improvement of visual acuity, whereas between 13% and 31% are likely to have worsening. The operative complication rate is low and similar to what has been reported for this procedure. These data provide estimates of surgical outcomes and serve as a reference for future studies that might consider vitrectomy for DME in eyes with at least moderate vision loss and vitreomacular traction.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, Research & Experimental

Effect of telephone calls from a centralized coordinating center on participant retention in a randomized clinical trial

Adam R. Glassman, Wesley T. Beaulieu, Cynthia R. Stockdale, Roy W. Beck, Neil M. Bressler, Leanne T. Labriola, Michele Melia, Kristina Oliver, Jennifer K. Sun

CLINICAL TRIALS (2020)

Article Ophthalmology

Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy

Maureen G. Maguire, Danni Liu, Adam R. Glassman, Lee M. Jampol, Chris A. Johnson, Carl W. Baker, Neil M. Bressler, Thomas W. Gardner, Dante Pieramici, Cynthia R. Stockdale, Jennifer K. Sun

JAMA OPHTHALMOLOGY (2020)

Article Ophthalmology

Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity A Secondary Analysis of a Randomized Clinical Trial

Adam R. Glassman, Carl W. Baker, Wesley T. Beaulieu, Neil M. Bressler, Omar S. Punjabi, Cynthia R. Stockdale, Charles C. Wykoff, Lee M. Jampol, Jennifer K. Sun

JAMA OPHTHALMOLOGY (2020)

Review Medicine, General & Internal

Evaluation and Care of Patients with Diabetic Retinopathy

Lee M. Jampol, Adam R. Glassman, Jennifer Sun

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Ophthalmology

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)

Adam R. Glassman, John A. Wells, Kristin Josic, Maureen G. Maguire, Andrew N. Antoszyk, Carl Baker, Wesley T. Beaulieu, Michael J. Elman, Lee M. Jampol, Jennifer K. Sun

OPHTHALMOLOGY (2020)

Editorial Material Ophthalmology

Are P Values Enough?

Adam R. Glassman

JAMA OPHTHALMOLOGY (2020)

Article Ophthalmology

Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning A Post Hoc Analysis of a Randomized Clinical Trial

Philipp K. Roberts, Wolf-Dieter Vogl, Bianca S. Gerendas, Adam R. Glassman, Hrvoje Bogunovic, Lee M. Jampol, Ursula M. Schmidt-Erfurth

JAMA OPHTHALMOLOGY (2020)

Editorial Material Ophthalmology

Interpreting Multiple Outcomes of Pupillary Light Reflex in Sport-Related Concussion in Adolescents

Wesley T. Beaulieu, Adam R. Glassman

JAMA OPHTHALMOLOGY (2020)

Article Medicine, General & Internal

Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial

Andrew N. Antoszyk, Adam R. Glassman, Wesley T. Beaulieu, Lee M. Jampol, Chirag D. Jhaveri, Omar S. Punjabi, Hani Salehi-Had, John A. Wells, Maureen G. Maguire, Cynthia R. Stockdale, Daniel F. Martin, Jennifer K. Sun

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Article Ophthalmology

Costs of Managing Diabetic Macular Edema With Good Visual Acuity With Aflibercept, Laser, or Observation: DRCR Retina Network Protocol V

David W. Hutton, Adam R. Glassman, Joshua D. Stein, Neil M. Bressler, Jennifer K. Sun

Summary: The study found that similar visual outcomes were obtained on average when managing CI-DME and good baseline VA patients initially with laser or observation strategies compared to the immediate use of aflibercept. While individual circumstances may warrant any of these three strategies, on a societal level, cost savings might be achieved with these first two approaches.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2021)

Article Ophthalmology

Optical Coherence Tomography Angiography Quality Across Three Multicenter Clinical Studies of Diabetic Retinopathy

Brandon J. Lujan, Claire T. Calhoun, Adam R. Glassman, Joseph M. Googe, Lee M. Jampol, Michele Melia, Deborah K. Schlossman, Jennifer K. Sun

Summary: This study investigated the quality of OCTA scans in multicenter clinical studies, showing that the majority of scans were of good quality. However, improvements are needed in signal strength and motion artifacts.

TRANSLATIONAL VISION SCIENCE & TECHNOLOGY (2021)

Article Ophthalmology

Effect of Initial Aflibercept, Laser, or Observation on Low-Contrast Visual Acuity in Eyes With Diabetic Macular Edema and Good Vision: Ancillary Study Within a Randomized Clinical Trial

Wesley T. Beaulieu, Adam R. Glassman, Carl W. Baker, Maureen G. Maguire, Chris A. Johnson, Michele Melia, Jennifer K. Sun

Summary: The study aimed to describe 2.5% low-contrast visual acuity in eyes with good vision despite center-involved diabetic macular edema and compare changes after different treatments. Results showed no significant difference in low-contrast visual acuity change from baseline to 2 years among treatment groups. However, due to the limited sample size, the study may not have had enough power to detect clinically meaningful benefits between treatment groups.

TRANSLATIONAL VISION SCIENCE & TECHNOLOGY (2021)

Article Ophthalmology

Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole DRCR Retina Network Protocols AG and AH

Clement K. Chan, Calvin E. Mein, Adam R. Glassman, Wesley T. Beaulieu, Claire T. Calhoun, Glenn J. Jaffe, Lee M. Jampol, Mathew W. MacCumber, Maureen G. Maguire, Raj K. Maturi, Hani Salehi-Had, Soraya Rofagha, Jennifer K. Sun, Daniel F. Martin

Summary: Pneumatic vitreolysis (PVL) showed effectiveness in releasing vitreomacular traction (VMT) in most eyes and closing full-thickness macular holes (FTMH) in approximately one third of eyes. However, safety concerns related to retinal detachments and tears led to early termination of the studies.

OPHTHALMOLOGY (2021)

Article Ophthalmology

Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy The Protocol W Randomized Clinical Trial

Raj K. Maturi, Adam R. Glassman, Kristin Josic, Andrew N. Antoszyk, Barbara A. Blodi, Lee M. Jampol, Dennis M. Marcus, Daniel F. Martin, Michele Melia, Hani Salehi-Had, Cynthia R. Stockdale, Omar S. Punjabi, Jennifer K. Sun

Summary: The study found that in eyes with moderate to severe NPDR, using aflibercept compared to sham treatment can reduce the proportion of eyes that develop proliferative diabetic retinopathy or non-center involved diabetic macular edema causing vision loss. However, preventive treatment did not confer visual acuity benefit compared with observation plus treatment with aflibercept only after development of PDR or vision-reducing CI-DME within two years.

JAMA OPHTHALMOLOGY (2021)

Article Ophthalmology

Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy A Secondary Analysis of a Randomized Clinical Trial

Adam R. Glassman, Wesley T. Beaulieu, Maureen G. Maguire, Andrew N. Antoszyk, Clement C. Chow, Michael J. Elman, Lee M. Jampol, Hani Salehi-Had, Jennifer K. Sun

Summary: This study compares exploratory outcomes between treatment groups for patients with vitreous hemorrhage due to proliferative diabetic retinopathy, finding that both initial aflibercept injections and vitrectomy with PRP are viable treatment options. Although no overall difference in mean visual acuity was noted between the groups, eyes that underwent vitrectomy with PRP had better visual acuity outcomes in the subgroup with baseline visual acuity worse than 20/800.

JAMA OPHTHALMOLOGY (2021)

暂无数据